Peripheral blood markers predict prognosis in patients with advanced non-small cell lung cancer receiving immunotherapy.
This study mainly explored the correlation between baseline peripheral blood biomarkers and prognosis in patients with advanced NSCLC undergoing immunotherapy. C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were independent predictors for both progression-free survival (PFS) and overall survival (OS).
This study mainly explored the correlation between baseline peripheral blood biomarkers and prognosis in patients with advanced NSCLC undergoing immunotherapy. C-reactive protein (CRP) and carcinoembryonic antigen (CEA) were independent predictors for both progression-free survival (PFS) and overall survival (OS).
What the study was
- Study design
- Observational cohort study
- Population
- In recent years, immunotherapy has significantly reshaped the pattern of non-small cell lung cancer (NSCLC) treatment.
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Medicine
Why it surfaced
Observational cohort study with abstract evidence; scored conservatively for novelty, clinical relevance, design quality, and population or unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.